<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110528006617N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-29</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Regional Scalp Block and Pin-Site Infiltration on Heart Rate and Blood Pressure</public_title>
      <acronym></acronym>
      <scientific_title>Assessment of the Effect of Regional Scalp Block and Pin-Site Infiltration on Heart Rate and Blood Pressure in Skull Pinning in Posterior Cervical Fusion Surgery: randomized control trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>102</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72391</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling in this research is done in two stages. In the first stage, samples will be entered continuously based on the criteria for entering the study. In the second stage, the samples are assigned to groups in the form of a random permutation block design of three groups with blocks of three. In this way, the letter A is for the regional Regional Scalp Block, group B is for the Pin-Site Infiltration, and the letter C is for the regional scalp block group. The control group is considered. Then, all substitution compounds will be extracted from the site below until the sample size reaches the quorum.
https://www.sealedenvelope.com/simple-randomiser/v1/lists
To avoid bias, this work will be done by someone other than the researcher, Blinding description: In this study, patients and people involved in data collection and analysis are not aware of the grouping.
After obtaining informed consent from eligible patients, they are randomly placed in 3 groups R, P and control, and the patients do not know which group they are in.
After general anesthesia, a skilled doctor injects the drug. In the first group, injection is done in 4 areas, in the second group, in two areas. In the third group, no injection is performed.
The person collecting the data does not know which group the patient belongs to.
The person responsible for analyzing the data does not know which group this data belongs to.</study_design>
      <phase>3</phase>
      <hc_freetext>Posterior cervical fusion surgery.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: Regional Scalp Block (RSB) In this group, with a 25-gauge needle, we inject a mixture of 0.5% bupivacaine 0.5% and 2cc dexamethasone (equivalent to 8mg) bilaterally in the 4 areas of the supra-trochlear, supra-orbital, zygomaticotemporal, and auricotemporal nerves with a 25-gauge needle. Intervention 2: Second intervention group: Pin-Site Infiltration (PSI) In this group, a mixture of 0.5% bupivacaine 0.5% and 2cc dexamethasone (equivalent to 8mg) is injected bilaterally at the pinning site with a 25 gauge needle. Intervention 3: Control group: They are only under general anesthesia. General anesthesia includes 1.5 to 2 mg/kg of propofol, 0.03 to 0.05 mcg/kg of fentanyl, and 0.5 mg/kg of atracurium.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehrdad Masoudifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>elective operating room, Al Zahra hospital, Soffeh Blvd, Isfahan, Isfahan province</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3822 0000</telephone>
        <email>masoudifar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrdad Masoudifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al Zahra hospital, Sofeh blv, Isfahan, Isfahan province</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3668 7898</telephone>
        <email>masoudifar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate patients for posterior cervical fusion surgery
Age 18 to 65 years
Completing the informed consent form
American Society of Anesthesiologists I, II</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Previous incision and previous history of cervical surgery
Allergy to local anesthetic
Drug or alcohol addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: Regional Scalp Block (RSB) In this group, with a 25-gauge needle, we inject a mixture of 0.5% bupivacaine 0.5% and 2cc dexamethasone (equivalent to 8mg) bilaterally in the 4 areas of the supra-trochlear, supra-orbital, zygomaticotemporal, and auricotemporal nerves with a 25-gauge needle.</i_keyword>
      <i_keyword>Second intervention group: Pin-Site Infiltration (PSI) In this group, a mixture of 0.5% bupivacaine 0.5% and 2cc dexamethasone (equivalent to 8mg) is injected bilaterally at the pinning site with a 25 gauge needle.</i_keyword>
      <i_keyword>Control group: They are only under general anesthesia. General anesthesia includes 1.5 to 2 mg/kg of propofol, 0.03 to 0.05 mcg/kg of fentanyl, and 0.5 mg/kg of atracurium.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: Basic time, from the time of intubation to the time of pinning every 3 minutes and from the time of injection to the time of surgical incision every 3 minutes. Method of measurement: Non invasive blood pressure.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: Basic time, from the time of intubation to the time of pinning every 3 minutes and from the time of injection to the time of surgical incision every 3 minutes. Method of measurement: Non invasive blood pressure.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Basic time, from the time of intubation to the time of pinning every 3 minutes and from the time of injection to the time of surgical incision every 3 minutes. Method of measurement: electrocardiogram(ECG).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Mean blood pressure. Timepoint: Basic time, from the time of intubation to the time of pinning every 3 minutes and from the time of injection to the time of surgical incision every 3 minutes. Method of measurement: Non invasive blood pressure.</sec_outcome>
      <sec_outcome>Saturation of Peripheral Oxygen (SPO2). Timepoint: Basic time, from the time of intubation to the time of pinning every 3 minutes and from the time of injection to the time of surgical incision every 3 minutes. Method of measurement: pulse oximetry.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-14</approval_date>
        <contact_name>Ethics Committee in Research Faculty of Medicine-Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezarjarib Street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
